Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randy F Sweis

Showing results (21-30 of 57) with videos related to

Pageof 6
Sort By:
Cancer Immunology Research|May 20, 2016
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerRandy F Sweis, Stefani Spranger, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|April 6, 2018
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerRandy F Sweis, Yuanyuan Zha, Lomax Pass, et al.
Frontiers in Immunology|March 22, 2024
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based modelDaniel R Bergman, Yixuan Wang, Erica Trujillo, et al.
Annals of Internal Medicine|October 21, 2014
Do clinicians know which of their patients have central venous catheters?: a multicenter observational studyVineet Chopra, Sushant Govindan, Latoya Kuhn, et al.
Cancers|September 14, 2024
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy EfficacyYixuan Wang, Daniel R Bergman, Erica Trujillo, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Cancer Immunology Research|January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid CellsKyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Clinical Genitourinary Cancer|September 17, 2016
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal CarcinomaRandy F Sweis, Milica Medved, Shannon Towey, et al.
Clinical Genitourinary Cancer|November 6, 2018
Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial CarcinomaJim Leng, Adil S Akthar, Russell Z Szmulewitz, et al.
Clinical Genitourinary Cancer|January 16, 2024
Bladder-Preserving Trimodality Therapy With CapecitabineConnor Lynch, Randy F Sweis, Parth Modi, et al.
Pageof 6

Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
Cancer Immunology Research|May 20, 2016
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder CancerRandy F Sweis, Stefani Spranger, Riyue Bao, et al.
Journal for Immunotherapy of Cancer|April 6, 2018
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancerRandy F Sweis, Yuanyuan Zha, Lomax Pass, et al.
Frontiers in Immunology|March 22, 2024
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based modelDaniel R Bergman, Yixuan Wang, Erica Trujillo, et al.
Annals of Internal Medicine|October 21, 2014
Do clinicians know which of their patients have central venous catheters?: a multicenter observational studyVineet Chopra, Sushant Govindan, Latoya Kuhn, et al.
Cancers|September 14, 2024
Agent-Based Modeling of Virtual Tumors Reveals the Critical Influence of Microenvironmental Complexity on Immunotherapy EfficacyYixuan Wang, Daniel R Bergman, Erica Trujillo, et al.
Investigational New Drugs|February 19, 2024
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinomaKathryn E Beckermann, Amita Patnaik, Ira Winer, et al.
Cancer Immunology Research|January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid CellsKyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Clinical Genitourinary Cancer|September 17, 2016
Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal CarcinomaRandy F Sweis, Milica Medved, Shannon Towey, et al.
Clinical Genitourinary Cancer|November 6, 2018
Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial CarcinomaJim Leng, Adil S Akthar, Russell Z Szmulewitz, et al.
Clinical Genitourinary Cancer|January 16, 2024
Bladder-Preserving Trimodality Therapy With CapecitabineConnor Lynch, Randy F Sweis, Parth Modi, et al.
Pageof 6